Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
Morgan Stanley has reiterated its Equalweight rating and $74.00 price target for shares of Globus Medical (NYSE: NYSE:GMED), following a recent FDA warning letter regarding the company's reporting practices for its Excelsius GPS system. The warning, which highlighted several substandard reporting methodologies, was posted on the FDA's website earlier in the day.
The analyst noted that while the optics of the warning letter could be concerning, they believe it does not impact the company's narrative post-NuVasive, nor does it relate to manufacturing or safety issues.
Despite the stock's approximate 8% decline, the analyst was surprised by the market's reaction, considering the concerns cited were largely administrative.
Globus Medical has already responded to the FDA's letter, which was dated July 15, 2024. The company had not disclosed the receipt of the warning letter during their recent second-quarter earnings call, as management deemed it immaterial. They have since addressed the required actions from the FDA.
Although the warning letter has not yet been resolved, the analyst understands that it does not restrict the commercial efforts for Excelsius GPS, nor does it necessitate any manufacturing changes or retrofits.
However, the letter could pose challenges for Pre-Market Approval (PMA) applications related to the Excelsius GPS technology. The analyst believes that Globus Medical was not actively seeking PMAs for the technology at this point.
Globus Medical reported a substantial increase in Q2 2024 sales, reaching $630 million, a 116% growth compared to the previous year. This impressive performance is attributed to the successful integration of NuVasive (NASDAQ:NUVA), a recent acquisition. Non-GAAP earnings per share also rose to $0.75, marking a 20% year-over-year increase.
Despite receiving a warning letter from the FDA regarding its manufacturing facilities, BTIG reaffirmed its Buy rating and $75.00 price target for Globus Medical. Similarly, Stifel maintained its Buy rating and $80.00 price target, expressing confidence in the company's ability to address the FDA's concerns without affecting its earnings potential.
In the wake of these developments, Globus Medical launched four new products and anticipates a record number of launches in the upcoming months. Analysts project full-year net sales to range between $2.47 billion and $2.49 billion, with non-GAAP EPS expected to land between $2.80 and $2.90. The company also aims to achieve $170 million in cost synergies and a mid-70s gross profit profile in the long term.
InvestingPro Insights
Amidst the recent FDA warning and market reactions, it's worth noting that Globus Medical (NYSE:GMED) is expected to have a positive financial outlook according to InvestingPro data. The company boasts a robust revenue growth of 103.89% in the last twelve months as of Q2 2024, with gross profit margins standing strong at 67.66%. These figures underscore the company's capacity to generate income efficiently from its operations.
Further reinforcing the company's financial health, InvestingPro Tips highlight that Globus Medical's management has been actively buying back shares, a sign of confidence in the company's value. Additionally, the company's cash flows are reported to be sufficient to cover interest payments, indicating a stable financial position. For investors looking for more detailed analysis and metrics, InvestingPro offers an additional 12 tips on their platform, providing a comprehensive view of the company's financial and operational performance.
Despite the high earnings multiple of 214.52, which may suggest a premium valuation, the adjusted P/E ratio for the last twelve months as of Q2 2024 is a more modest 33.79. This adjustment provides a clearer picture of the company's earnings relative to its share price. With a market capitalization of $9.07 billion and a price close to its 52-week high, Globus Medical remains a significant player in the medical devices industry. Investors can find a fair value estimate of $76.99 on InvestingPro, offering a benchmark for potential investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.